Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)

Eisai

Status: Completed

Conditions: Inoperable or Recurrent Breast Cancer

Treatments: Drug: Eribulin Mesylate

Study type: Observational

Funder types: Industry

Identifiers

NCT01463891

HAL01S

Details and patient eligibility

About

To investigate of the clinical safety and effectiveness of eribulin mesylate in patients with inoperable or recurrent breast cancer

Enrollment: 963 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria :

• Inoperable breast cancer
• Recurrent breast cancer

Exclusion criteria :

• Corresponding to contraindication of eribulin mesylate
• Not applicable to indications of eribulin mesylate
• Not applicable to aggravation or recurrence of breast cancer in patients who have previously been treated with anthracycline and/or taxane antitumor drugs

Trial design

963 participants in 1 patient group

Eribulin Mesylate

Treatment:

Drug: Eribulin Mesylate